• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of September 30

Article

The Center for Biosimilars® recaps the top stories for the week of September 30, 2019.

Transcript

Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 30, 2019.

Number 5: A new report from the House Ways and Means Committee finds that Americans pay nearly 4 times more for drugs than do patients in other countries.

Number 4: During the week’s European Society for Medical Oncology Congress 2019, a research team presented findings from a phase 3 trial of Samsung Bioepis' proposed bevacizumab biosimilar.

Number 3: New research suggests that state-level drug price transparency laws are largely ineffective at revealing true transaction prices.

Number 2: A newly introduced item of legislation proposes to eliminate co-payments for patients when they receive biosimilars in Medicare Part B.

Number 1: Pfizer says that it will launch its bevacizumab biosimilar, Zirabev, in the United States on December 31.

Finally, last week, our e-newsletter asked whether you think that biosimilars of rituximab will make treatment more accessible for patients with neurological diseases like multiple sclerosis.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Related Content
© 2024 MJH Life Sciences

All rights reserved.